IL277095B1 - Preparations containing anti-PD-1 antibody - Google Patents
Preparations containing anti-PD-1 antibodyInfo
- Publication number
- IL277095B1 IL277095B1 IL277095A IL27709520A IL277095B1 IL 277095 B1 IL277095 B1 IL 277095B1 IL 277095 A IL277095 A IL 277095A IL 27709520 A IL27709520 A IL 27709520A IL 277095 B1 IL277095 B1 IL 277095B1
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- seq
- amino acid
- acid sequence
- sequence shown
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Claims (18)
1. A pharmaceutical composition comprising or consisting of: an anti-PD-1 antibody of 150 mg/ml; a histidine buffer of 20 mM ; a disaccharide of 84 mg/ml trehalose; 0.2 mg/ml PS80; and a chelating agent of 0.045 or 0.05 mg/ml EDTA, wherein said pharmaceutical composition is pH 5.0 +/- 0.1, and the anti-PD-1 antibody is an IgG4 human or humanized monoclonal antibody comprising a heavy chain variable region (VH) comprising a VH complementarity determining region one (CDR1), a VH CDR2, and a VH CDR3; and a light chain variable region (VL) comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 4, the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 5, and the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 6, the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 7, the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 8, and the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 9.
2. The pharmaceutical composition of claim 1, wherein the viscosity of the composition is between 10 cP and 18 cP at at 20ºC.
3. The pharmaceutical composition of claim 2, wherein the viscosity of the composition is 15 cP at 20ºC.
4. The pharmaceutical composition of claim 1, comprising or consisting essentially of: 150 mg/ml anti-PD-1 antibody; mM histidine buffer; 100 mM arginine HCl; mg/ml trehalose; 277095/ - 67 - 0.2 mg/ml PS80; and 0.045 or 0.05 mg/ml EDTA, wherein said pharmaceutical composition is pH 5.0 +/- 0.1.
5. The pharmaceutical composition of claim 4, wherein the viscosity of the composition is between 10 cP and 18 cP at at 20ºC.
6. The pharmaceutical composition of claim 5, wherein the viscosity of the composition is 15 cP at 20ºC.
7. The pharmaceutical composition of any one of claims 1 to 6 , wherein the EDTA comprises disodium EDTA, disodium EDTA dihydrate, or a combination of disodium EDTA and disodium EDTA dihydrate.
8. The pharmaceutical composition of any one of claims 1 to 7 , wherein the antibody is an human or humanized IgG4 monoclonal antibody comprising a heavy chain variable region (VH) comprising the amino acid sequence shown in SEQ ID NO: 2, and a light chain variable region (VL) comprising the amino acid sequence shown in SEQ ID NO: 3.
9. The pharmaceutical composition of any one of claims 1 to 8, wherein the antibody comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 10, with or without the C-terminal lysine of SEQ ID NO: 10; and a light chain comprising the amino acid sequence shown in SEQ ID NO: 11.
10. The pharmaceutical composition of claim 9, wherein the antibody displays glycosylation at Asn294 comprising G0F and G1F as the main glycan species.
11. The pharmaceutical composition of claim 10, wherein the glycosylation further comprises as minor glycan species truncated and/or afucosylated complex-type biantennary structures, a high mannose-type Man5 structure, and sialylated, core-fucosylated complex-type biantennary oligosaccharides.
12. A pharmaceutical composition comprising or consisting essentially of: 150 mg/ml anti-PD-1 antibody, wherein the antibody comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 10, with or 277095/ - 68 - without the C-terminal lysine of SEQ ID NO: 10; and a light chain comprising the amino acid sequence shown in SEQ ID NO: 11; mM histidine buffer; mg/ml trehalose; 0.2 mg/ml PS80; and 0.045 or 0.05 mg/ml EDTA, wherein said pharmaceutical composition is pH 5.0 +/- 0.1 and has a viscosity of to 18 cP at 20ºC.
13. The pharmaceutical composition of claim 12, wherein the EDTA comprises disodium EDTA, disodium EDTA dihydrate, or a combination of disodium EDTA and disodium EDTA dihydrate.
14. The pharmaceutical composition of claim 12 or 13, wherein the trehalose is trehalose dihydrate.
15. The pharmaceutical composition of any one of claims 1 to 14, wherein the pharmaceutical composition does not comprise an anti-oxidant.
16. The pharmaceutical composition of claim 15, wherein the anti-oxidant is L-methionine, or a pharmaceutically acceptable salt thereof.
17. The pharmaceutical composition of any one of claims 1 to 16, wherein the pharmaceutical composition does not comprise methionine.
18. The pharmaceutical composition of any one of claims 1 to 17, wherein the pharmaceutical composition does not comprise arginine.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639587P | 2018-03-07 | 2018-03-07 | |
| US201962807912P | 2019-02-20 | 2019-02-20 | |
| PCT/IB2019/051733 WO2019171253A1 (en) | 2018-03-07 | 2019-03-04 | Anti-pd-1 antibody compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL277095A IL277095A (en) | 2020-10-29 |
| IL277095B1 true IL277095B1 (en) | 2025-06-01 |
| IL277095B2 IL277095B2 (en) | 2025-10-01 |
Family
ID=66041593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL277095A IL277095B2 (en) | 2018-03-07 | 2019-03-03 | Anti-pd-1 antibody compositions |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210002369A1 (en) |
| EP (1) | EP3761954A1 (en) |
| JP (1) | JP7312188B2 (en) |
| KR (1) | KR102594028B1 (en) |
| CN (1) | CN112105343B (en) |
| AU (1) | AU2019232625B2 (en) |
| BR (1) | BR112020017935A2 (en) |
| IL (1) | IL277095B2 (en) |
| MX (1) | MX2020009275A (en) |
| WO (1) | WO2019171253A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| PE20212185A1 (en) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | FORMULATION OF THERAPEUTIC ANTIBODIES |
| AU2020385048A1 (en) * | 2019-11-13 | 2022-06-02 | Pfizer Inc. | Stable aqueous anti-TFPI antibody formulation |
| TW202138006A (en) * | 2019-12-13 | 2021-10-16 | 韓商三星Bioepis股份有限公司 | Stable anti-pd-1 antibody pharmaceutical formulations |
| US20230355757A1 (en) | 2019-12-20 | 2023-11-09 | Formycon Ag | Formulations of anti-pd1 antibodies |
| WO2021152175A1 (en) * | 2020-01-31 | 2021-08-05 | Sanofi | Pulmonary delivery of antibodies |
| CA3181776A1 (en) | 2020-05-26 | 2021-12-02 | Boehringer Ingelheim International Gmbh | Anti-pd-1 antibodies |
| CN113967195A (en) * | 2020-07-22 | 2022-01-25 | 三生国健药业(上海)股份有限公司 | anti-HER 2/PD1 bispecific antibody lyophilized preparation and preparation method thereof |
| CN114652824A (en) * | 2020-12-23 | 2022-06-24 | 上海药明生物技术有限公司 | anti-EGFR and PD-1 bispecific antibody formulations and methods of preservation |
| US20240287185A1 (en) | 2021-06-23 | 2024-08-29 | Formycon Ag | Formulations of anti-pd1 antibodies |
| CN117881419A (en) * | 2021-07-01 | 2024-04-12 | 天津立博美华基因科技有限责任公司 | Drug combinations and their uses |
| CA3224640A1 (en) * | 2021-07-09 | 2023-01-12 | Krishnan SAMPATHKUMAR | Pharmaceutical compositions of a pd-1 antibody and use of the same |
| JP2024532462A (en) * | 2021-09-03 | 2024-09-05 | ドクター レディズ ラボラトリーズ リミテッド | Methods for improving the stability of immune checkpoint inhibitors |
| CN118076380A (en) * | 2021-09-03 | 2024-05-24 | 雷迪博士实验室有限公司 | Pharmaceutical formulations of immune checkpoint inhibitors |
| MX2024009994A (en) * | 2022-03-07 | 2024-08-22 | Mabxience Res S L | Stable formulations for antibodies. |
| US20260207493A1 (en) * | 2022-12-21 | 2026-07-23 | Formycon Ag | Formulations of anti-pd1 antibodies |
| WO2024171082A1 (en) | 2023-02-16 | 2024-08-22 | Sun Pharmaceutical Industries Limited | Stable protein compositions of anti-pd1 antibody |
| TW202508641A (en) * | 2023-08-16 | 2025-03-01 | 大陸商上海邁晉生物醫藥科技有限公司 | A pharmaceutical composition containing immune conjugate and use thereof |
| WO2025174319A1 (en) * | 2024-02-16 | 2025-08-21 | Xbrane Biopharma Ab | Stable antibody formulation for intravenous use comprising nivolumab, histidine, sucrose, polysorbate and methionine |
| SE548163C2 (en) * | 2024-02-16 | 2026-04-13 | Xbrane Biopharma Ab | Stable antibody formulation comprising nivolumab, histidine, sucrose, polysorbate and methionine |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015048520A1 (en) * | 2013-09-27 | 2015-04-02 | Genentech, Inc. | Anti-pdl1 antibody formulations |
| US20160159905A1 (en) * | 2014-12-09 | 2016-06-09 | Rinat Neuroscience Corp. | Anti-pd-1 antibodies and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP1865986B1 (en) | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| CA2602316A1 (en) * | 2005-03-23 | 2006-09-28 | Pfizer Products Inc. | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (en) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | ANTIBODIES FOR THE PD-1 PROGRAMMED DEATH HUMAN RECEPTOR |
| EA201500417A1 (en) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | ANTAGONIST COMPOSITIONS PD-1 AND APPLICATIONS |
| MX2012012927A (en) * | 2010-05-06 | 2013-05-01 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies. |
| BR112013025845A2 (en) * | 2011-04-07 | 2018-09-04 | Glaxosmithkline Llc | low viscosity formulations |
| TWI731535B (en) * | 2014-03-21 | 2021-06-21 | 美商艾伯維有限公司 | Anti-egfr antibodies and antibody drug conjugates |
| TW201617368A (en) * | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | Novel anti-MFI2 antibody and method of use |
| WO2016120753A1 (en) * | 2015-01-28 | 2016-08-04 | Pfizer Inc. | Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation |
| EP3357508A4 (en) * | 2015-09-28 | 2019-04-24 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | PHARMACEUTICAL PREPARATION OF STABLE ANTI-PD-1 ANTIBODIES AND APPLICATION THEREOF IN A MEDICAMENT |
| WO2017055966A1 (en) * | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
| SG11201909941QA (en) * | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| US10646569B2 (en) * | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
-
2019
- 2019-03-03 IL IL277095A patent/IL277095B2/en unknown
- 2019-03-04 AU AU2019232625A patent/AU2019232625B2/en active Active
- 2019-03-04 WO PCT/IB2019/051733 patent/WO2019171253A1/en not_active Ceased
- 2019-03-04 EP EP19715555.9A patent/EP3761954A1/en active Pending
- 2019-03-04 MX MX2020009275A patent/MX2020009275A/en unknown
- 2019-03-04 US US16/978,354 patent/US20210002369A1/en active Pending
- 2019-03-04 BR BR112020017935-3A patent/BR112020017935A2/en unknown
- 2019-03-04 CN CN201980030480.7A patent/CN112105343B/en active Active
- 2019-03-04 KR KR1020207028149A patent/KR102594028B1/en active Active
- 2019-03-04 JP JP2020546926A patent/JP7312188B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015048520A1 (en) * | 2013-09-27 | 2015-04-02 | Genentech, Inc. | Anti-pdl1 antibody formulations |
| US20160159905A1 (en) * | 2014-12-09 | 2016-06-09 | Rinat Neuroscience Corp. | Anti-pd-1 antibodies and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021517129A (en) | 2021-07-15 |
| BR112020017935A2 (en) | 2021-02-09 |
| AU2019232625A1 (en) | 2020-09-17 |
| CA3093036A1 (en) | 2019-09-12 |
| AU2019232625B2 (en) | 2025-12-11 |
| EP3761954A1 (en) | 2021-01-13 |
| CN112105343B (en) | 2024-07-30 |
| RU2020129226A3 (en) | 2022-04-07 |
| KR20200128115A (en) | 2020-11-11 |
| US20210002369A1 (en) | 2021-01-07 |
| CN112105343A (en) | 2020-12-18 |
| KR102594028B1 (en) | 2023-10-24 |
| JP7312188B2 (en) | 2023-07-20 |
| WO2019171253A8 (en) | 2020-10-01 |
| IL277095A (en) | 2020-10-29 |
| WO2019171253A1 (en) | 2019-09-12 |
| IL277095B2 (en) | 2025-10-01 |
| RU2020129226A (en) | 2022-04-07 |
| MX2020009275A (en) | 2021-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277095B2 (en) | Anti-pd-1 antibody compositions | |
| JP7375122B2 (en) | Humanized, murine or chimeric anti-CD47 monoclonal antibodies | |
| JP2021517129A5 (en) | ||
| JP4879884B2 (en) | Anti-IL-9 antibody preparation and use thereof | |
| US12264199B2 (en) | Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies | |
| ES2433092T3 (en) | Compositions and production procedures of a composition | |
| ES2626033T3 (en) | High concentration antibody formulations | |
| JP5933975B2 (en) | Antibody preparation | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| RU2012131099A (en) | ANTIBODY DRUG | |
| JP2020015719A (en) | Pertuzumab variants and evaluation thereof | |
| PE20240814A1 (en) | STABLE FORMULATIONS OF ANTIBODIES AGAINST THE PROGRAMMED DEATH 1 (PD-1) RECEPTOR AND METHODS FOR THEIR USE | |
| US20220056126A1 (en) | Anti-lag-3 antibodies and compositions | |
| JP2020518600A5 (en) | ||
| CO6251275A2 (en) | FORMULATIONS OF LIOFILIZED IMMUNOGLOBULIN AND METHODS FOR PREPARATION | |
| CN111971062A (en) | Monoclonal antibody preparation for resisting human PD-1, combined medicament and application thereof | |
| HRP20211444T1 (en) | Anti-dll3 antibody | |
| JP2020518598A5 (en) | ||
| MY182680A (en) | Antibody formulation and therapeutic regimens | |
| PE20140882A1 (en) | NEUTRALIZING ANTIBODIES OF HUMAN CYTOMEGALOVIRUS | |
| CA3091174A1 (en) | B7-h4 antibody formulations | |
| JP2020518600A (en) | Stable formulations of anti-TIGIT antibodies, alone and in combination with programmed death receptor 1 (PD-1) antibodies, and methods of use thereof | |
| JP2016533335A5 (en) | ||
| HRP20230146T1 (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition | |
| WO2017060322A3 (en) | Ptefb-inhibitor-adc |